BIOQUAL, Inc.
BIOQ
$43.19
-$0.25-0.58%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -8.54% | -28.19% | -24.45% | 8.76% | -4.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.54% | -28.19% | -24.45% | 8.76% | -4.84% |
| Cost of Revenue | -13.05% | -13.68% | -9.73% | -5.71% | 2.28% |
| Gross Profit | 16.42% | -104.48% | -85.54% | 625.15% | -30.35% |
| SG&A Expenses | -25.93% | -13.58% | -15.50% | 8.64% | 8.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.85% | -13.67% | -10.47% | -3.94% | 3.07% |
| Operating Income | 384.83% | -423.54% | -196.95% | 114.99% | -69.20% |
| Income Before Tax | 240.53% | -350.13% | -175.07% | 123.55% | -63.44% |
| Income Tax Expenses | 240.98% | -350.24% | -175.07% | 122.15% | -65.63% |
| Earnings from Continuing Operations | 240.36% | -350.09% | -175.08% | 124.13% | -62.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 240.36% | -350.09% | -175.08% | 124.13% | -62.54% |
| EBIT | 384.83% | -423.54% | -196.95% | 114.99% | -69.20% |
| EBITDA | 100.48% | -202.09% | -128.35% | 188.47% | -49.69% |
| EPS Basic | 240.33% | -350.10% | -175.07% | 124.13% | -62.54% |
| Normalized Basic EPS | 240.53% | -350.13% | -175.07% | 123.55% | -63.44% |
| EPS Diluted | 240.33% | -351.85% | -175.57% | 124.13% | -62.67% |
| Normalized Diluted EPS | 240.53% | -350.13% | -175.07% | 123.55% | -63.44% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -1.40% | -- | -- | 0.33% |